ASP:CA:TSX-Acerus Pharmaceuticals Corporation (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | TSX

Last Closing Price

CAD 0.05

Change

0.00 (0.00)%

Market Cap

CAD 0.07B

Volume

0.33M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. In addition, the company provides TriVair technology platform that offer applications for pulmonary and nasal pharmaceutical medications. Acerus Pharmaceuticals Corporation sells products through its salesforce in the United States; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada. Address: 2486 Dunwin Drive, Mississauga, ON, Canada, L5L 1J9

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-23 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
WEED:CA Canopy Growth Corporation

N/A

CAD16.00B N/A N/A
BHC:CA Bausch Health Companies Inc

N/A

CAD12.05B N/A 29.10
APHA:CA Aphria Inc

N/A

CAD5.22B 57.08 598.01
CRON:CA Cronos Group Inc

N/A

CAD4.83B 47.21 N/A
ACB:CA Aurora Cannabis Inc

N/A

CAD2.49B 1,171.00 N/A
HEXO:CA HEXO Corp

N/A

CAD1.03B N/A N/A
CWEB:CA Charlotte's Web Holdings, Inc

N/A

CAD0.83B 120.37 N/A
GUD:CA Knight Therapeutics Inc

N/A

CAD0.74B 28.39 7.22
HLS:CA HLS Therapeutics Inc

N/A

CAD0.57B N/A 40.85
OGI:CA OrganiGram Holdings Inc

N/A

CAD0.51B -99,999.99 N/A

ETFs Containing ASP:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.50% 26% F 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.50% 26% F 88% B+
Trailing 12 Months  
Capital Gain -31.16% 41% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.16% 41% F 8% F
Trailing 5 Years  
Capital Gain -60.28% 33% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.28% 33% F 7% F
Average Annual (5 Year Horizon)  
Capital Gain 1.23% 65% D 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.23% 65% D 39% F
Risk Return Profile  
Volatility (Standard Deviation) 79.50% 30% F 7% F
Risk Adjusted Return 1.54% 65% D 33% F
Market Capitalization 0.07B 27% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 5.00 59% F 87% B+
Price/Book Ratio 2,017.93 3% F 0% N/A
Price / Cash Flow Ratio -6.08 50% F 84% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -182.58% 7% F 2% F
Return on Assets -83.32% 3% F 1% F
Debt to Equity Ratio -155.79% 100% A+ 97% A+
Technical Ratios  
Short Ratio 0.21 80% B- 72% C-
Short Percent N/A N/A N/A N/A N/A
Beta 1.00 81% B- 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector